REVIEW article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1572997
Homocysteine and thyroid diseases
Provisionally accepted
- 1Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
- 2College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Homocysteine (Hcy) is an important intermediate product in methionine metabolism which plays a key role in the methylation of DNA, RNA and proteins.High level of Hcy can induce endothelial cell damage, promote the release of inflammatory factors, stimulate oxidative stress and inhibit the fibrinolytic system.Numerous studies have confirmed the close relationship between hyperhomocysteinemia (HHcy) and the occurrence/development of various diseases such as cardiovascular diseases, neurological disorders, thrombotic diseases, and tumors. With the rising incidence of thyroid diseases, the relationship between Hcy and thyroid diseases has attracted widespread attention. It has been found that HHcy may be directly or indirectly associated with the development of hypothyroidism, but the findings with hyperthyroidism, chronic lymphocytic thyroiditis and reduced thyroid hormone sensitivity are controversial. This article reviews the research progress of Hcy and thyroid diseases, with a view to providing new ideas for the prevention and clinical treatment of diseases.
Keywords: Homocysteine, Hyperhomocysteinemia, Hypothyroidism, Hyperthyroidism, MTHFR
Received: 08 Feb 2025; Accepted: 25 Jun 2025.
Copyright: © 2025 Cui, Wang, Li, Liu, Wang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Haipeng Wang, College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong Province, China
Junyu Zhao, Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, 250014, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.